We are on a mission to improve the lives of those living with addiction and to have a broad, positive impact on society.
Together, we can bring psilocybin to the market to empower those who currently don’t have any other assuring options.
Psilocybin has the potential to effectively treat alcoholism, as demonstrated through clinical studies.
B.More is named after Brett Moore, who died of a drug overdose 50 years ago and was the brother of our co-founder, Claudia Turnbull. To keep his name alive and help others suffering from substance use disorders, B.More came into being.
B.More is a 501(c)(3) non-profit lifescience company studying psilocybin, a classic psychedelic, to treat patients suffering from Alcohol Use Disorder (AUD) and who may have been unsuccessful with more traditional drug and treatment programs.
The Leading Team
Facing worldwide problems as big as alcoholism and forms of substance use disorders require a committed team of experts.
B.More’s foundation is established upon collaborations with leading institutions, renowned key researchers in AUD and addiction, a leadership team, and scientific advisors steeped in experience to deliver value in breakthrough treatments to this overlooked population.
Founder and CEO
Since 2010 Mr. Turnbull has worked in commercial early-stage drug development for half a dozen companies variously as an investor, founder, and CEO.
He is on the advisory board of the NYU School of Medicine Department of Psychiatry Psychedelic Research Group, for the Psilocybin Alcohol Use Disorder study, and has assisted in the founding of Yale University’s extensive psilocybin research program. Mr. Turnbull is a member of the board of two Foundations: Heffter Research Institute and Usona Institute, both of which promote research on psychedelic plants and drugs at leading University research departments.
Chief Operating Officer
20+ years Pharmaceutical Project Management
Judy Ashworth, MD
Chief Medical Officer
20+ years Analgesic & CNS Drug Development
Chief Scientific Officer
40+ years Quality Assurance & CMC Development
Stephan Loose, MBA
Chief Commercial Officer
15+ years Pharmaceutical Commercialization & Business Development
10+ years Clinical Development of CNS drugs
Shayne Gad, PhD, DABT
Pharmacology & Toxicology
40+ years Toxicology & Pharmacology
20+ years Regulatory Pharmaceutical Strategist
Ryan Lanier, PhD
20+ years Pre-Clinical & Clinical Development of CNS Drugs
Lutfiya Miller, PhD, DABT
10+ years Pharmaceutical
15+ years Quality Assurance GMP
Board of Directors
Founder, Pennant Investors, LLC
Founder, The Fournier Family Foundation
30 years, biopharmaceutical
Founder & Director MindMed
Stephen Hurst, JD
AMFT, M.A. Existential-Phenomenological Counseling Psychology
Executive Director, Riverstyx Foundation
T. Cody Swift
Advisory Board Member, NYU School of Medicine Department of Psychiatry Psychedelic Research Group, for the Psilocybin Alcohol Use Disorder study
Board Member, Heffter Research Institute
Board Member, Usona Institute
Founder & CEO, Ceruvia Lifesciences
Co-founder & CEO, B.More
Investigator, Johns Hopkins Center for Psychedelic and Consciousness Research
Board Member, Heffter Research Institute
Board Member, Ceruvia Lifesciences
Board of Trustees, College of the Atlantic
Partners & Collaborators
New York University (NYU) School of Medicine, one of the nation’s premier academic medical centers, has newly created the NYU Langone Center for Psychedelic Medicine, which conducts trials focusing on substance abuse disorder research. NYU Langone Health Psychiatrist, Dr. Michael Bogenschutz and his capable clinical team are the Lead site for the B.More Phase 2 AUD study using Psilocybin.
Emmes is a global, full-service clinical research organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation.
Founded in 1977, Emmes has conducted over 2000 clinical studies across a broad range of therapeutic areas, with significant expertise in neurology and the management of studies using schedule 1 drugs. Emmes manages B.More’s Phase 2 AUD study with site support, enrollment, statistical programming, data management and site management/monitoring, and analysis.
Usona Institute is a non-profit medical research organization dedicated to supporting and conducting pre-clinical and clinical research to understand further the therapeutic effects of psilocybin and other consciousness-expanding medicines. Their focus is on alleviating depression in people whose current medical treatments fall short in offering relief and a better quality of life.
Usona has manufactured pharmaceutical-grade psilocybin and is currently conducting the necessary comprehensive pre-clinical toxicology work for prescription medication, enabling B.More’s FDA clinical trials.
The Heffter Research Institute promotes the highest-quality scientific research with classic hallucinogens and related compounds (sometimes called psychedelics) to better understand how the mind improves the human condition and alleviates suffering.
B.More seeks to take academic research Heffter has been instrumental in developing at elite universities and pivot it into prescription medication development trials required by FDA.